Pulmonary Pharmacology

Correct Answer

B — Albuterol

Rationale

Albuterol is a selective beta-2 adrenergic receptor agonist used as a short-acting rescue bronchodilator. Ipratropium and tiotropium are muscarinic receptor antagonists (anticholinergic bronchodilators), not adrenergic agonists. Theophylline is a methylxanthine that acts primarily by inhibiting phosphodiesterase enzymes.

Correct Answer

D — Tiotropium

Rationale

Tiotropium is classified as a long-acting muscarinic antagonist, providing once-daily bronchodilation through sustained muscarinic receptor blockade. Ipratropium is also a muscarinic antagonist but is short-acting, requiring dosing four times daily. Albuterol and salmeterol are beta-2 adrenergic receptor agonists, not muscarinic antagonists.

Correct Answer

A — Salmeterol

Rationale

Salmeterol is classified as a long-acting beta-2 adrenergic receptor agonist with a duration of approximately 12 hours, used for maintenance rather than rescue therapy. Albuterol is a short-acting beta-2 agonist. Ipratropium and tiotropium are muscarinic antagonists, not beta-2 agonists.

Correct Answer

C — Ipratropium

Rationale

Ipratropium is a short-acting muscarinic antagonist with a duration of approximately 4 to 6 hours, used for acute bronchodilation in COPD and as an adjunct in acute severe asthma. Tiotropium is also a muscarinic antagonist but is long-acting, dosed once daily. Formoterol and salmeterol are long-acting beta-2 adrenergic receptor agonists.

Correct Answer

B — Formoterol

Rationale

Formoterol is classified as a full agonist at the beta-2 adrenergic receptor, producing maximal receptor activation per unit of receptor occupancy. Salmeterol, by contrast, is a partial agonist — it occupies beta-2 receptors but produces submaximal activation even at full receptor occupancy. Tiotropium and ipratropium are muscarinic antagonists, not beta-2 receptor ligands.

Correct Answer

A — The isolated R-enantiomer of albuterol

Rationale

Levalbuterol is the isolated R-enantiomer of albuterol and represents the pharmacologically active form responsible for beta-2 receptor agonism. Racemic albuterol contains both the active R-enantiomer and the inactive S-enantiomer in equal proportions. Levalbuterol is not a prodrug and is not derived from enzymatic conversion after inhalation.

Correct Answer

C — Gs activation → adenylyl cyclase → increased cyclic AMP → protein kinase A → myosin light chain kinase inhibition

Rationale

Beta-2 adrenergic receptors couple to Gs proteins, which activate adenylyl cyclase to raise intracellular cyclic AMP. Cyclic AMP activates protein kinase A, which phosphorylates and inhibits myosin light chain kinase, reducing myosin phosphorylation and causing smooth muscle relaxation and bronchodilation. The Gq pathway (option A) drives bronchoconstriction, not bronchodilation, and is the pathway activated by muscarinic M3 receptors. Gi activation (option B) would reduce cyclic AMP. Option D incorrectly pairs Gs with phospholipase C, which is the effector for Gq, not Gs.

Correct Answer

A — Beta-2 receptor stimulation increases skeletal muscle sodium-potassium ATPase activity, driving potassium into cells

Rationale

Beta-2 adrenergic receptor stimulation increases sodium-potassium ATPase activity in skeletal muscle, shifting potassium from the extracellular space into cells and lowering serum potassium concentration. This is a transcellular redistribution, not increased renal excretion. The effect is dose-dependent and clinically significant in acute severe asthma, where it is additive with hypokalemic effects of concurrent corticosteroids and loop diuretics.

Correct Answer

D — Its onset of action is 10 to 20 minutes, too slow to relieve acute bronchoconstriction

Rationale

Salmeterol has a slow onset of 10 to 20 minutes, which reflects its lipophilic side chain anchoring it to the lipid bilayer near the receptor before diffusing to the binding site. This slow onset makes it entirely unsuitable for acute rescue use, where relief must occur within minutes. Salmeterol is indeed a beta-2 agonist with bronchodilatory activity and a long duration of approximately 12 hours; the clinical limitation is onset speed, not duration or receptor class.

Correct Answer

B — The SMART trial demonstrated increased asthma-related deaths with salmeterol used without inhaled corticosteroids

Rationale

The SMART trial (Salmeterol Multicenter Asthma Research Trial) was terminated early because of a statistically significant increase in asthma-related deaths in the salmeterol monotherapy group compared with placebo. This finding established that LABAs must never be used as monotherapy in asthma and must always be combined with an inhaled corticosteroid. The mechanism of increased mortality is not fully understood but likely reflects inadequate anti-inflammatory control when bronchodilation masks worsening airway inflammation. LABAs do not cause bronchoconstriction, do not produce irreversible receptor blockade, and cardiac arrhythmia is not the basis for this specific warning.

Correct Answer

C — Tiotropium dissociates much more slowly from M3 receptors than from M2 receptors, allowing M2 autoreceptor function to recover

Rationale

Tiotropium achieves functional M3 selectivity through differential receptor dissociation kinetics rather than differential binding affinity. It dissociates very slowly from M3 receptors (half-life of dissociation approximately 34 hours) but far more rapidly from M2 autoreceptors. This kinetic difference means that M2 autoreceptors recover function between doses, restoring their normal negative feedback role of limiting acetylcholine release, while M3 receptors on airway smooth muscle remain blocked for 24 hours. The result is sustained bronchodilation with preservation of prejunctional M2 feedback — a pharmacokinetically mediated functional selectivity.

Correct Answer

A — PDE3 is the principal isoform in airway smooth muscle; PDE4 is the dominant isoform in inflammatory cells such as eosinophils and mast cells

Rationale

Phosphodiesterase 3 is the principal cyclic AMP-degrading isoform in airway smooth muscle; its inhibition prolongs bronchodilation by preventing cyclic AMP breakdown. Phosphodiesterase 4 is the dominant isoform in inflammatory cells, including eosinophils, mast cells, neutrophils, and macrophages; its inhibition reduces inflammatory mediator release. This distinction explains why the selective PDE4 inhibitor roflumilast is used for its anti-inflammatory effect in COPD rather than as a primary bronchodilator. Both isoforms degrade cyclic AMP, not cyclic GMP; the substrate distinction and the isoform-to-tissue assignments in option D are both reversed.

Correct Answer

D — Ipratropium is poorly absorbed systemically after inhalation, limiting drug delivery to systemic muscarinic receptors

Rationale

Ipratropium is a quaternary ammonium compound that is poorly absorbed from the airway mucosa and gastrointestinal tract after inhalation. This limited systemic absorption is the primary reason it produces far fewer systemic anticholinergic effects (dry mouth, urinary retention, tachycardia, blurred vision) than atropine at doses that produce equivalent bronchodilation. Ipratropium is not receptor-selective — it blocks M1, M2, and M3 receptors with similar affinity, just as atropine does. Its advantage is pharmacokinetic, not pharmacodynamic.

Correct Answer

B — Formoterol is a full agonist with a rapid onset of 1 to 3 minutes, enabling immediate rescue bronchodilation

Rationale

Formoterol qualifies for dual maintenance and rescue use in the SMART strategy because of two specific pharmacological properties: it is a full agonist (producing maximal receptor activation) and has a rapid onset of 1 to 3 minutes, comparable to albuterol. Salmeterol is a partial agonist with a slow onset of 10 to 20 minutes and cannot provide the rapid relief required of a rescue agent. Option D describes a real clinical practice (budesonide/formoterol combination) but misidentifies the pharmacological reason — the ICS partner reduces the risk of uncontrolled inflammation with LABA use, but the ability to serve as a rescue agent rests on formoterol's own pharmacological properties.

Correct Answer

C — Beta-2 receptor activation in skeletal muscle slow-twitch fibers produces tremor that is dose-dependent

Rationale

Skeletal muscle tremor is the most common systemic adverse effect of beta-2 adrenergic agonists and results from direct beta-2 receptor activation in slow-twitch muscle fibers. The effect is dose-dependent and is most pronounced at higher doses, explaining why increasing the albuterol dose produced noticeable tremor in this patient. The tremor is a peripheral effect — it does not require central nervous system penetration. Hypokalemia from beta-2 stimulation is a real adverse effect but causes weakness rather than tremor and acts through potassium redistribution, not membrane depolarization from electrolyte loss alone.

Correct Answer

A — Tiotropium blocks M3 receptors on bladder detrusor smooth muscle, reducing the contractile force needed to initiate and sustain voiding

Rationale

Muscarinic M3 receptors are the principal effectors of smooth muscle contraction throughout the body — in the airway, in the gut, and in the bladder detrusor. Tiotropium blocks M3 receptors wherever systemic drug exposure reaches, and in a patient with pre-existing prostatic enlargement, even modest reduction in detrusor contractility can tip the balance toward urinary hesitancy or retention. This is a predictable extension of M3 receptor pharmacology beyond the airway. The same receptor subtype that drives bronchoconstriction when stimulated drives detrusor contraction when stimulated; blocking it for airway benefit simultaneously impairs bladder emptying in susceptible patients. Urinary retention is a recognized contraindication-relative to tiotropium use in patients with significant bladder outflow obstruction.

Correct Answer

D — Add an inhaled corticosteroid to the salmeterol, because LABAs must never be used as monotherapy in asthma

Rationale

The SMART trial established that long-acting beta-2 agonists increase asthma-related mortality when used without an inhaled corticosteroid, which is the basis for the LABA black box warning. The required correction is not to stop the LABA or increase its dose, but to add an inhaled corticosteroid — LABAs are effective and appropriate maintenance bronchodilators in asthma when combined with ICS, which provides the anti-inflammatory coverage that prevents the mortality risk. Switching to formoterol does not eliminate the safety concern; the black box warning applies to the entire LABA class, not to salmeterol specifically. Stopping the LABA and using albuterol alone would leave this patient with moderate persistent asthma on rescue-only therapy without any controller, which is also inappropriate.

Correct Answer

B — Each drug lowers serum potassium by a different mechanism, and their combined hypokalemic effects are additive

Rationale

All three agents lower serum potassium through distinct mechanisms. Albuterol stimulates beta-2 receptors in skeletal muscle, increasing sodium-potassium ATPase activity and driving potassium into cells — a transcellular shift. Systemic corticosteroids such as methylprednisolone activate mineralocorticoid receptors in the renal collecting duct, increasing urinary potassium excretion. Furosemide inhibits the sodium-potassium-chloride cotransporter in the thick ascending limb, reducing potassium reabsorption and increasing urinary losses. Because the three mechanisms are independent and their potassium-lowering effects sum, the combination can produce clinically significant hypokalemia even at doses that individually would cause only modest reductions.